FY2026 EPS Estimates for Labcorp Raised by Leerink Partnrs

Labcorp Holdings Inc. (NYSE:LH) – Stock analysts at Leerink Partnrs boosted their FY2026 EPS estimates for Labcorp in a research note issued on Thursday, July 24th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will post earnings per share of $17.99 for the year, up from their previous forecast of $17.73. The consensus estimate for Labcorp’s current full-year earnings is $16.01 per share. Leerink Partnrs also issued estimates for Labcorp’s FY2028 earnings at $22.54 EPS.

LH has been the subject of several other research reports. UBS Group set a $305.00 price target on Labcorp and gave the company a “buy” rating in a report on Friday, July 25th. Robert W. Baird increased their target price on Labcorp from $290.00 to $302.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. Barclays reissued a “cautious” rating on shares of Labcorp in a report on Wednesday, June 25th. Morgan Stanley upped their price target on shares of Labcorp from $283.00 to $306.00 and gave the company an “overweight” rating in a research note on Friday, July 25th. Finally, HSBC cut shares of Labcorp from a “buy” rating to a “hold” rating and set a $260.00 price objective for the company. in a research note on Thursday, July 10th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $285.00.

Labcorp Trading Down 0.2%

Shares of LH stock opened at $261.36 on Monday. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $21.88 billion, a price-to-earnings ratio of 28.85, a price-to-earnings-growth ratio of 1.68 and a beta of 0.82. Labcorp has a 12-month low of $209.38 and a 12-month high of $283.47. The stock’s 50-day moving average price is $254.87 and its 200-day moving average price is $244.99.

Labcorp (NYSE:LH) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $4.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.14 by $0.21. Labcorp had a net margin of 5.66% and a return on equity of 15.45%. The company had revenue of $3.53 billion for the quarter, compared to the consensus estimate of $3.49 billion. During the same period in the previous year, the firm posted $3.94 EPS. Labcorp’s revenue for the quarter was up 9.6% compared to the same quarter last year.

Labcorp Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 11th. Investors of record on Thursday, August 28th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.10%. Labcorp’s payout ratio is 31.79%.

Insider Buying and Selling

In other Labcorp news, EVP Der Vaart Sandra D. Van sold 1,900 shares of the business’s stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $238.36, for a total transaction of $452,884.00. Following the completion of the transaction, the executive vice president owned 2,244 shares in the company, valued at $534,879.84. The trade was a 45.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Brian J. Caveney sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $247.00, for a total value of $494,000.00. Following the transaction, the executive vice president directly owned 30,067 shares in the company, valued at approximately $7,426,549. This represents a 6.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 15,334 shares of company stock worth $3,908,714 over the last three months. 0.84% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Labcorp

Several hedge funds have recently bought and sold shares of LH. Brighton Jones LLC bought a new stake in shares of Labcorp during the fourth quarter valued at approximately $991,000. LPL Financial LLC increased its holdings in Labcorp by 63.8% during the 4th quarter. LPL Financial LLC now owns 62,546 shares of the medical research company’s stock worth $14,343,000 after purchasing an additional 24,357 shares during the period. Korea Investment CORP raised its position in Labcorp by 36.0% during the 4th quarter. Korea Investment CORP now owns 37,058 shares of the medical research company’s stock valued at $8,498,000 after purchasing an additional 9,800 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Labcorp by 11.4% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 133,349 shares of the medical research company’s stock valued at $30,557,000 after purchasing an additional 13,661 shares in the last quarter. Finally, UniSuper Management Pty Ltd lifted its holdings in shares of Labcorp by 16.9% in the 4th quarter. UniSuper Management Pty Ltd now owns 10,488 shares of the medical research company’s stock worth $2,405,000 after buying an additional 1,519 shares during the period. Institutional investors own 95.94% of the company’s stock.

Labcorp Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.